#Trulicity
LightNews LightNews
thatgaytiefling.bsky.social
I forgot to put my trulicity back in the fridge yesterday and thought I fucked everything up but it turns out it can actually be at room temperature for two weeks. I of course put t back in immediately on realizing it but still good to know
November 3, 2026 at 5:46 PM
bettycjung.bsky.social
Eli Lilly's tirzepatide and dulaglutide are sold under the brand names Mounjaro and Trulicity for diabetes.

The other half were taking metformin, a gold-standard generic medication prescribed for prediabetes.
November 4, 2026 at 3:11 AM
higekieiyu.bsky.social
Guh... starting to feel barfy.

Wonder if that's the new Trulicity dose or if I just happen to feel barfy...
October 28, 2026 at 11:50 PM
higekieiyu.bsky.social
I think I can already tell the new dose of Trulicity is going to work well.
October 28, 2026 at 6:06 PM
fallah.bsky.social
Today's Bisexual Agenda

✅clean up breakfast
◽️complete ballot
✅Work Stuff (slide deck)
◽️put away laundry
◽️call Mom
◽️fill pill box
◽️Trulicity
✅ New CGM sensor (uhhh probably something else I forgot)
October 25, 2026 at 8:45 PM
fallah.bsky.social
With credit to @majima.space for the format

Today's Bisexual Agenda

◽️clean up breakfast
◽️complete ballot
◽️Work Stuff (slide deck)
◽️put away laundry
◽️call Mom
◽️fill pill box
◽️Trulicity
◽️uhhh probably something else I forgot
October 25, 2026 at 3:59 PM
thesocialjusticegm.bsky.social
I'm down from 320 to 288 on Trulicity.
October 24, 2026 at 4:23 PM
fallah.bsky.social
Got distracted by video games 🙃

✅have also had lunch & dinner

✅clean up breakfast
◽️complete ballot
✅Work Stuff (slide deck)
◽️put away laundry
◽️call Mom
✅fill pill box
◽️Trulicity
✅ New CGM sensor (uhhh probably something else I forgot) 
October 26, 2026 at 12:23 AM
fallah.bsky.social
✅have also had lunch & dinner

✅clean up breakfast
◽️complete ballot
✅Work Stuff (slide deck)
✅put away laundry
✅call Mom
✅fill pill box
◽️Trulicity
✅ New CGM sensor (uhhh probably something else I forgot)  
October 26, 2026 at 1:45 AM
letyourheartfly.bsky.social
I see. It's very complicated😔 I've been on weight loss stuff for years and nothing stuck until I started trulicity for my diabetes. That and Ive been a bit too lazy to cook big meals all the time like I used to lol
October 26, 2026 at 11:56 PM
midgardfinance.eu
🇩🇰 #$NOVO Q3 adjusted operating profit DKK 31.7bn, +34% (+27% at constant FX); Novo credits GLP-1 sales and a Q3 2025 base with c. 9bn transformation costs, less c. 3.5bn one-offs now. Reported 23.0bn after 8.7bn impairments. 2026 outlook up again.

midgardfinance.com/companies/NOVO-B.CO/
Waterfall chart titled "Novo Nordisk: operating profit in Q3, DKK bn": Novo Nordisk's operating profit from Q3 2025 to Q3 2026 in billions of kroner, rounded to one decimal. Q3 2025: 23.7, adjusted and reported the same. Novo says Q3 2025 carried about DKK 9bn of costs for its company-wide transformation, which do not recur, and Q3 2026 about 3.5bn of one-time costs. Currency added 1.6. The rest, +0.9, is our arithmetic of what remains. Adjusted operating profit Q3 2026: 31.7, +34% in kroner and +27% at constant exchange rates. Impairments of 8.7 (ziltivekimab 4.6, the manufacturing network 4.1) leave reported 23.0, −3% in kroner and −9% at constant exchange rates. Line chart titled "Novo Nordisk: obesity and diabetes, DKK bn": Novo Nordisk's adjusted sales by quarter in billions of kroner from Q1 2018, obesity medicines (blue: Wegovy injection and pill, Saxenda) against diabetes medicines (grey: Ozempic, Ozempic pill/Rybelsus, Victoza, insulin, other diabetes). Obesity from 0.8 to 26.1 in Q3 2026, +22% at constant exchange rates; diabetes from 20.8, a peak of 58.6 in Q4 24, to 47.5, −5%. Blood and endocrine disorders are not shown. Grouped bar chart titled "Novo vs Lilly: GLP-1 outside the US, €bn": quarterly revenue from GLP-1 medicines outside the US in billions of euros since Q1 24, International Operations for Novo Nordisk. Novo (blue) from 2.1 to 3.3 in Q3 26; Lilly (light blue: Mounjaro, Zepbound and Trulicity outside the US) from 0.6 to 5.3 in Q3 26. Lilly does not split Foundayo by region, so it is left out, while Novo's line holds the Wegovy pill outside the US (€0.16bn in Q3 2026). Mounjaro outside the US is sold for diabetes and obesity without a split. Bar chart titled "Novo Nordisk: 2026 outlook": Novo Nordisk's outlook for 2026 growth in adjusted sales and adjusted operating profit at constant exchange rates, the same range for both each time, low and high end at each step. 3 Feb: −13% to −5%; 6 May: −12% to −4%; 4 Aug: −6% to 0%; 4 Nov: −2% to +2%.
November 4, 2026 at 7:40 AM
midgardfinance.com
🇩🇰 #$NOVO Q3 adjusted operating profit DKK 31.7bn, +34% (+27% at constant FX); Novo credits GLP-1 sales and a Q3 2025 base with c. 9bn transformation costs, less c. 3.5bn one-offs now. Reported 23.0bn after 8.7bn impairments. 2026 outlook up again.

midgardfinance.com/companies/NOVO-B.CO/
Waterfall chart titled "Novo Nordisk: operating profit in Q3, DKK bn": Novo Nordisk's operating profit from Q3 2025 to Q3 2026 in billions of kroner, rounded to one decimal. Q3 2025: 23.7, adjusted and reported the same. Novo says Q3 2025 carried about DKK 9bn of costs for its company-wide transformation, which do not recur, and Q3 2026 about 3.5bn of one-time costs. Currency added 1.6. The rest, +0.9, is our arithmetic of what remains. Adjusted operating profit Q3 2026: 31.7, +34% in kroner and +27% at constant exchange rates. Impairments of 8.7 (ziltivekimab 4.6, the manufacturing network 4.1) leave reported 23.0, −3% in kroner and −9% at constant exchange rates. Line chart titled "Novo Nordisk: obesity and diabetes, DKK bn": Novo Nordisk's adjusted sales by quarter in billions of kroner from Q1 2018, obesity medicines (blue: Wegovy injection and pill, Saxenda) against diabetes medicines (grey: Ozempic, Ozempic pill/Rybelsus, Victoza, insulin, other diabetes). Obesity from 0.8 to 26.1 in Q3 2026, +22% at constant exchange rates; diabetes from 20.8, a peak of 58.6 in Q4 24, to 47.5, −5%. Blood and endocrine disorders are not shown. Grouped bar chart titled "Novo vs Lilly: GLP-1 outside the US, €bn": quarterly revenue from GLP-1 medicines outside the US in billions of euros since Q1 24, International Operations for Novo Nordisk. Novo (blue) from 2.1 to 3.3 in Q3 26; Lilly (light blue: Mounjaro, Zepbound and Trulicity outside the US) from 0.6 to 5.3 in Q3 26. Lilly does not split Foundayo by region, so it is left out, while Novo's line holds the Wegovy pill outside the US (€0.16bn in Q3 2026). Mounjaro outside the US is sold for diabetes and obesity without a split. Bar chart titled "Novo Nordisk: 2026 outlook": Novo Nordisk's outlook for 2026 growth in adjusted sales and adjusted operating profit at constant exchange rates, the same range for both each time, low and high end at each step. 3 Feb: −13% to −5%; 6 May: −12% to −4%; 4 Aug: −6% to 0%; 4 Nov: −2% to +2%.
November 4, 2026 at 7:45 AM
midgardfinance.com
💉💊 #obesity

🇩🇰 #$NOVO Q3 GLP-1 sales worldwide €8.1bn, 🇺🇸 #$LLY €14.9bn, mostly tirzepatide. #Wegovy pill €722m in its 3rd quarter on sale (the 1st included stocking), #Foundayo €160m in its 2nd. US Wegovy incl. pill +21% at constant FX, injection −13%.

midgardfinance.com/research/novonordisk/
Line chart titled "Novo vs Lilly: GLP-1 sales by quarter, €bn": quarterly revenue from GLP-1 medicines in billions of euros since Q1 19. Novo Nordisk (blue: Ozempic, Wegovy injection and pill, Ozempic pill/Rybelsus, Victoza, Saxenda) from 1.1 to 8.1 in Q3 26. Eli Lilly (light blue: Trulicity, Mounjaro, Zepbound, Foundayo) from 0.8 to 14.9 in Q3 26. Lilly has been above Novo every quarter since Q2 25. Each company's own currency converted at the quarter's average rate; Novo's are adjusted sales, equal to reported in Q3 2026. Lilly's Mounjaro and Zepbound act on GIP as well as GLP-1. Lilly says its Q3 revenue held about €0.8bn of milestones and rebate estimate changes, €0.36bn of them Jardiance milestones outside these medicines. Bar chart titled "Novo Nordisk: Q3 growth at constant FX": Novo Nordisk's sales growth in Q3 2026 against Q3 2025 at constant exchange rates, in the US (left panel) and outside it (right panel), by product: All products US +1%, outside +8%; Wegovy injection + pill US +21%, outside +31%; Wegovy injection US −13%, outside +16%; Ozempic US −11%, outside +8%; Ozempic pill / Rybelsus US +5%, outside −19%; Insulin US −13%, outside +8%; Blood & endocrine US +27%, outside +6%. Novo says a one-off prior-period adjustment helped Ozempic outside the US, but loss of exclusivity in Canada offset it. The Wegovy pill has no growth rate, as it launched in 2026. Bar chart titled "Novo vs Lilly: US obesity brands, €bn": quarterly US revenue in billions of euros from the obesity brands, Q1 2024 to Q3 2026, each company's own currency converted at the quarter's average rate. Novo Nordisk's Wegovy as a stacked bar, the injection (blue) with the pill (green) on top from Q1 2026, beside Eli Lilly's Zepbound (light blue). Wegovy 1.1 in Q1 2024; the injection alone peaked at 2.0 in Q4 24; then 1.5 from the injection and 0.56 from the pill, 2.04 together, in Q3 2026. Zepbound 0.5 in Q1 2024 and 4.6 in Q3 2026. Lilly says its lower US prices were driven mainly by Zepbound and partly offset by changes to rebate estimates. Lilly's Foundayo pill has no US figure of its own and is left out, and Mounjaro, which Lilly does not split by use, is not counted as obesity. Grouped bar chart titled "Novo vs Lilly: obesity pills, €m": worldwide revenue in millions of euros of the two GLP-1 pills for obesity, lined up by quarter on sale. Wegovy pill (Novo Nordisk, green), launched in the US on 5 January 2026 and by the end of Q3 also in the UAE, the UK and Germany: Q1 26 302; Q2 26 431; Q3 26 722. Foundayo (Eli Lilly, light blue), launched in the US on 9 April 2026: Q2 26 84; Q3 26 160. Foundayo's first quarter was not a whole one, as it went on sale on the quarter's ninth day. Novo says the Wegovy pill's first quarter was lifted by stocking at wholesalers and telehealth partners before launch; in Q3 2026 €559m of its €722m was in the US. Novo's Ozempic pill/Rybelsus, for diabetes, is not shown.
November 4, 2026 at 7:45 AM
midgardfinance.eu
💉💊 #obesity

🇩🇰 #$NOVO Q3 GLP-1 sales worldwide €8.1bn, 🇺🇸 #$LLY €14.9bn, mostly tirzepatide. #Wegovy pill €722m in its 3rd quarter on sale (the 1st included stocking), #Foundayo €160m in its 2nd. US Wegovy incl. pill +21% at constant FX, injection −13%.

midgardfinance.com/research/novonordisk/
Line chart titled "Novo vs Lilly: GLP-1 sales by quarter, €bn": quarterly revenue from GLP-1 medicines in billions of euros since Q1 19. Novo Nordisk (blue: Ozempic, Wegovy injection and pill, Ozempic pill/Rybelsus, Victoza, Saxenda) from 1.1 to 8.1 in Q3 26. Eli Lilly (light blue: Trulicity, Mounjaro, Zepbound, Foundayo) from 0.8 to 14.9 in Q3 26. Lilly has been above Novo every quarter since Q2 25. Each company's own currency converted at the quarter's average rate; Novo's are adjusted sales, equal to reported in Q3 2026. Lilly's Mounjaro and Zepbound act on GIP as well as GLP-1. Lilly says its Q3 revenue held about €0.8bn of milestones and rebate estimate changes, €0.36bn of them Jardiance milestones outside these medicines. Bar chart titled "Novo Nordisk: Q3 growth at constant FX": Novo Nordisk's sales growth in Q3 2026 against Q3 2025 at constant exchange rates, in the US (left panel) and outside it (right panel), by product: All products US +1%, outside +8%; Wegovy injection + pill US +21%, outside +31%; Wegovy injection US −13%, outside +16%; Ozempic US −11%, outside +8%; Ozempic pill / Rybelsus US +5%, outside −19%; Insulin US −13%, outside +8%; Blood & endocrine US +27%, outside +6%. Novo says a one-off prior-period adjustment helped Ozempic outside the US, but loss of exclusivity in Canada offset it. The Wegovy pill has no growth rate, as it launched in 2026. Bar chart titled "Novo vs Lilly: US obesity brands, €bn": quarterly US revenue in billions of euros from the obesity brands, Q1 2024 to Q3 2026, each company's own currency converted at the quarter's average rate. Novo Nordisk's Wegovy as a stacked bar, the injection (blue) with the pill (green) on top from Q1 2026, beside Eli Lilly's Zepbound (light blue). Wegovy 1.1 in Q1 2024; the injection alone peaked at 2.0 in Q4 24; then 1.5 from the injection and 0.56 from the pill, 2.04 together, in Q3 2026. Zepbound 0.5 in Q1 2024 and 4.6 in Q3 2026. Lilly says its lower US prices were driven mainly by Zepbound and partly offset by changes to rebate estimates. Lilly's Foundayo pill has no US figure of its own and is left out, and Mounjaro, which Lilly does not split by use, is not counted as obesity. Grouped bar chart titled "Novo vs Lilly: obesity pills, €m": worldwide revenue in millions of euros of the two GLP-1 pills for obesity, lined up by quarter on sale. Wegovy pill (Novo Nordisk, green), launched in the US on 5 January 2026 and by the end of Q3 also in the UAE, the UK and Germany: Q1 26 302; Q2 26 431; Q3 26 722. Foundayo (Eli Lilly, light blue), launched in the US on 9 April 2026: Q2 26 84; Q3 26 160. Foundayo's first quarter was not a whole one, as it went on sale on the quarter's ninth day. Novo says the Wegovy pill's first quarter was lifted by stocking at wholesalers and telehealth partners before launch; in Q3 2026 €559m of its €722m was in the US. Novo's Ozempic pill/Rybelsus, for diabetes, is not shown.
November 4, 2026 at 7:40 AM
nahlan.net
There’s also Trulicity and Victozy depending on your medical needs, so you have three options they’ll conver over Mounjaro.
October 21, 2026 at 4:42 AM
betweencases.bsky.social
Medicare drug price negotiation, cycle 3, includes Part B drugs for the first time: Botox, Entyvio, Orencia, Xolair, Cosentyx, Trulicity, Biktarvy and more. Makers must accept or reject CMS's final offers by Oct 31. Prices start in 2028.
Free weekday intel: betweencases.beehiiv.com
October 21, 2026 at 12:02 PM
travis-j25.bsky.social
www.cnbc.com/2026/05/20/e...
Eli Lilly accuses church bishops, businessmen of fraud in Trulicity drug rebate scheme
Eli Lilly claims in a civil lawsuit that it's the victim of a $200 million plus drug rebate fraud tied to Pentecostal church bishops and businesses.
www.cnbc.com
October 20, 2026 at 12:15 PM
sapphixy.bsky.social
Let me be clear: I don't care if you, personally, go on Ozempic or Mounjaro or Trulicity or whatever because you're desperate to lose those last stubborn ten pounds. You should definitely be fully informed of the risks to your gut health and endocrine system, because no exogenous medication is…
October 18, 2026 at 6:09 PM
mtannenbaum.bsky.social
Whoever that person is, that is an idiotic, poorly informed view. I am sure they take plenty of OTC meds and/or anti-biotics when they are ill. Trulicity was approved more than a dozen years ago to treat diabetes. There is tons of data that these drugs are safe.
mikemikeike.bsky.social MikeIke @mikemikeike.bsky.social · 16d
I tried talking to someone IRL about this the other day and it seemed like the bottom line was a distrust of pharma cos, which I can at least understand. But, like I told them, I trust GLP1s because rich people got them first. If they were risky, The Kardashian’s wouldn’t have been the first users
October 18, 2026 at 7:24 PM
archaicpyro.bsky.social
think our trulicity is doing *too* well, we skip it every other week but on the weeks we take it it is consistently dropping us into the low 50s i didn't really want to deal with this rn
October 15, 2026 at 8:26 AM
auntie-jafo.bsky.social
Tuesdays are usually 5% battery for me because of my weekly Trulicity injection.
But this morning, I had all sorts of weird energy.
But right now in the late afternoon,
Toddler's Epic Bike Fail
ALT: Toddler's Epic Bike Fail
static.klipy.com
October 14, 2026 at 12:33 AM
drbenweitz.bsky.social
GLP-1 medications, such as Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, and Trulicity, have been linked to nail detachment (4 times as likely), hair loss, and scalp inflammation, according to an international study www.sciencedaily.com/releases/202...
Popular weight loss drugs linked to a surprising fingernail problem
Popular GLP-1 weight loss drugs, such as Ozempic and Wegovy, have been linked to unexpectedly high rates of nail detachment, hair loss, and scalp inflammation, with some problems occurring several tim...
www.sciencedaily.com
October 15, 2026 at 11:48 AM
riptodeesse.blacksky.app
Maybe trulicity? The appetite suppressant factor isn’t as strong with that one

Also, is your A1C low enough to switch over to oral meds?
October 13, 2026 at 10:07 PM
bluebird2002.bsky.social
If not for his being a non alcohol person, I’d say he’s drunk.
In addition He might try the weekly shot to drop off 50 to 60 pounds.
I take a version (Trulicity) for diabetes and I am down 65 pounds.
October 14, 2026 at 12:26 AM